New data from a pair of studies about the side effects of Pradaxa have raised concerns about the dangers of the blood thinning drug. Studies conducted by the Food and Drug Administration and the manufacturer of Pradaxa point to a link between the bloodthinner and a risk of severe gastrointestinal bleeding or other major bleeding…
The anticoagulant Pradaxa may increase the risk and severity of viral flu infections, according to researchers at the University of North Carolina. A study that reported on the team’s findings was published in the March 2013 issue of the Journal of Clinical Investigation.
A report by the Food and Drug Administration has linked the blood thinner Pradaxa to more than 500 deaths in 2011 alone. Medical experts have accused the FDA of not subjecting Pradaxa to sufficiently rigorous testing before the drug was approved for sale, stating that Pradaxa carries unique risks not found with other blood thinning…
A non-profit organization formed by the Food and Drug Administration and other health groups has criticized the agency’s safety analysis of the blood thinning drug Pradaxa. According to data released by the Observational Medical Outcomes Project (OMOP), the FDA’s analysis of the risk of bleeding risk caused by Pradaxa may have been flawed, causing the…
Lawyers involved in the ongoing litigation over the drug Pradaxa have predicted that hundreds of lawsuits may eventually be filed by patients who were injured after taking the medication. Pradaxa is an anti-clotting drug that is prescribed to prevent stroke in patients with a common type of heart rhythm abnormality.
PRADAXA is a prescription blood-thinning drug made by Boehringer Ingelheim. It was approved by the FDA in October of 2010 to reduce the risk of stroke and blood clots in people with atrial fibrillation. Since its approval, the drug has been linked to serious and life-threatening bleeding risks.